[PDF][PDF] Neurotheranostics as personalized medicines

JE McMillan, S Gorantla, TK Bronich, B Edagwa… - 2018 - researchgate.net
Bhavesh D. Kevadiya a, Brendan M. Ottemann a, Midhun Ben Thomas a, Insiya Mukadam b,
Saumya Nigam a, JoEllyn McMillan a, Santhi Gorantla a, Tatiana K. Bronich b, Benson …

[HTML][HTML] Neurotheranostics as personalized medicines

BD Kevadiya, BM Ottemann, MB Thomas… - Advanced Drug Delivery …, 2019 - Elsevier
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic
clinical outcomes for neurological disorders. Research was facilitated, in largest measure …

Neurotherapeutics: Concept, Translation, Transition

AI Faden - Neurotherapeutics, 2014 - Springer
The mission of ASENT is to facilitate the clinical translation of basic neuroscience
discoveries to improve the treatment of neurological and psychiatric disorders. When …

Nanotheranostics: the future remedy of neurological disorders

S Sohail - Cancer Nanotheranostics: Volume 2, 2021 - Springer
Informative Abstract Clinical results were not improved by therapies aimed at the central
nervous system. Because drugs cannot pass across the blood-brain barrier, the most …

Neurotherapeutics [electronic resource]: Emerging Strategies

LM Pullan, J Patel - sidalc.net
Neuroscience's inherent complexity and rapid growth mean that no one can keep abreast of
all the changes across the field. We each bring a necessarily narrow perspective …

Handbook of Contemporary Neuropharmacology. Three Volume Set. 2007. Edited by David R. Sibley, Israel Hanin, Michael Kuhar, Phil Skolnick. Published by John …

S Roth - Canadian Journal of Neurological Sciences, 2008 - cambridge.org
During the past few decades, the disciplines of neuroscience and neuropharmacology have
advanced dramatically. This has contributed to a better understanding of the functions of the …

[HTML][HTML] Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?

SJ Wang, A Fotenos, SC Masters, L Marzella - Theranostics, 2022 - ncbi.nlm.nih.gov
Background Diagnosis and therapy share a nuanced relationship in medicine. While most
patients experience diagnosis prior to therapy in temporal sequence, causal linkages …

Phase 3 NEURO-TTRansform Findings Signify Eplontersen as Promising Agent for hATTR Polyneuropathy.

M Meglio - Neurology Live, 2023 - go.gale.com
About a month after Ionis Pharmaceuticals announced positive results from its phase 3
NEURO-TTRansform study (NCT04136184) assessing its investigational agent eplontersen …

Nanotheranostics, a future remedy of neurological disorders

M Sharma, T Dube, S Chibh, A Kour… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Effective therapy of various neurological disorders is hindered on account of
the failure of various therapeutics crossing blood-brain-barrier (BBB). Nanotheranostics has …

Changing Times at CNS Neuroscience & Therapeutics: Formerly CNS Drug Reviews http://www. blackwellpublishing. com/CNSNT

MH Pollack - CNS Neuroscience & Therapeutics, 2008 - ncbi.nlm.nih.gov
It is an honor, privilege and indeed, challenge to take over as Editor of CNS Neuroscience
and Therapeutics. Formerly entitled CNS Drug Review, this journal grew under the direction …